Viatris and mapi pharma to highlight latest results of multiple sclerosis research at american academy of neurology 75th annual meeting

Meeting program to feature latest clinical findings for ga depot and showcase commitment to improving care for people living with multiple sclerosis (ms) pittsburgh , april 24, 2023 /prnewswire/ -- viatris inc. (nasdaq: vtrs), a global healthcare company, and mapi pharma today announced that recent data from ongoing studies of ga depot 40 mg will be presented at the american academy of neurology (aan) 75th annual meeting in boston taking place april 22-27. data will include results from the pivotal phase iii clinical trial exploring the efficacy and safety of ga depot – a long-acting glatiramer acetate being investigated as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis (rms).
VTRS Ratings Summary
VTRS Quant Ranking